Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6446786 | 0.92 | CYP3A4 (0.68) | CYP3A4HPGDALDH1A1C5AR1ADORA3 | |
| SCHEMBL1031237 | 0.88 | HPGD (0.73) | CYP3A4HPGDALDH1A1C5AR1MAPT | |
| SCHEMBL3979221 | 0.86 | HPGD (0.68) | CYP3A4HPGDALDH1A1C5AR1ADORA3 | |
| SCHEMBL31213513 | 0.84 | HPGD (0.52) | CYP3A4HPGDC5AR1ADORA3ADORA1 | |
| SCHEMBL29142975 | 0.83 | CYP3A4 (1.00) | CYP3A4HPGDALDH1A1C5AR1ADORA3 | |
| SCHEMBL2330664 | 0.82 | ALDH1A1 (0.47) | CYP3A4HPGDALDH1A1ADORA1ADORA2A | |
| SCHEMBL9197469 | 0.82 | HPGD (0.51) | CYP3A4HPGDADORA3ADORA1ADORA2A | |
| SCHEMBL3240884 | 0.81 | HPGD (0.54) | CYP3A4HPGDADORA3ADORA2A | |
| SCHEMBL1030465 | 0.80 | CYP3A4 (0.59) | CYP3A4HPGDALDH1A1C5AR1MAPT | |
| SCHEMBL239409 | 0.79 | ALDH1A1 (0.45) | CYP3A4HPGDALDH1A1ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435740-B2 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435740-B2 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435740-B2 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20060178385-A1 | Novel adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2006-08-10 | — | — | US | disclosed |
| US-5696124-A | Xanthine derivatives with adenosine-antagonistic activity | BOEHRINGER INGELHEIM KG (DE) | 1997-12-09 | — | — | US | disclosed |
| US-5688802-A | TREATMENT OF ALZHEIMER'S DISEASE, ORGANIC BRAIN SYNDROME, PARKINSON'S DISEASE, SENILE DEMENTIA | BOEHRINGER INGELHEIM KG | 1997-11-18 | — | — | US | disclosed |
| US-5532368-A | CHOLINOMIMETIC AGENTS; ALZHEIMER*S DISEASE; CENTRAL NERVOUS SYSTEM DISORDERS | BOEHRINGER INGELHEIM GMBH (DE) | 1996-07-02 | — | — | US | disclosed |
| EP-0374808-B1 | Xanthin derivatives having an adenosin-antagonist activity | BOEHRINGER INGELHEIM KG (DE) | 1996-04-17 | — | — | EP | disclosed |
| US-5175291-A | Reaction of 1,4-dioxaspiro 4,4!nonan-7-carboxylic acid with carbonyldiimidazole with 5,6-diamino-1,3-dipropyluracil in the presence of calcium hydroxide and hydroxylating | BOEHRINGER INGELHEIM KG (DE) | 1992-12-29 | — | — | US | disclosed |
| EP-0374808-A2 | Xanthin derivatives having an adenosin-antagonist activity | BOEHRINGER INGELHEIM KG (DE) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178385-A1 | Novel adenosine A3 receptor modulators | ADORA3, ADORA2A, ADORA1 | CYP3A4 1808/4885HPGD 2552/4885ALDH1A1 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.